This resolution expresses the sense of the House of Representatives that policies affecting access to medication abortion care must be grounded in transparent scientific review and the full body of medical evidence. It asserts that over 25 years of real-world evidence and hundreds of peer-reviewed studies confirm mifepristone's safety and effectiveness , a fact that should be respected in law and policy. The resolution highlights that the Food and Drug Administration (FDA) has repeatedly affirmed mifepristone's safety through rigorous scientific reviews, even when prescribed via telemedicine and dispensed by mail or pharmacy. The resolution further states that Congress granted the FDA authority to regulate prescription drugs based on scientific determinations, free from political interference. It emphasizes the critical importance of preserving and expanding access to medication abortion care , including the ability to prescribe mifepristone through telemedicine and dispense it by mail or at a pharmacy. This expanded access is deemed essential to ensure equitable care for patients disproportionately harmed by existing statutory, regulatory, financial, and circumstantial restrictions, including: Black and Indigenous people people of color immigrants people with lower incomes people in rural communities LGBTQ+ people people living with disabilities people experiencing intimate partner violence and other marginalized communities.